Global Molecular Diagnostics at the Point of Care Markets, 2022-2027: COVID-19 Pandemic Drives Point of Care Diagnostics into Hypergrowth
Dublin, April 18, 2022 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics at the Point of Care: By Application, Technology, Place, Product and by Country, with COVID-19 PoC Breakout and Executive Guides" report has been added to ResearchAndMarkets.com's offering.
Make investment decisions and valuations with confidence using the latest data andfive year market forecasts.
The COVID-19 pandemic is ushering in a new world of point of care diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.
Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Point of Care testing move into the Physician's Office or even the Home? How much Covid-19 testing is being done at the Point of Care?
Point of Care testing is proving itself in the market. Players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time.
Key Topics Covered:
Market Trends
Factors Driving Growth
New Genotypes Creating New Markets
Aging Population a Boon for All Diagnostics
Developing World Driving ID Dx Growth
Point of Care - Why Centralization is Losing Steam
Self Testing
The Need for Speed
The COVID Pandemic
Factors Limiting Growth
Lower Costs
Infectious Disease is Declining
Wellness Hurts
Economic Growth improves Living Standards
Instrumentation and Automation
Instruments Key to Market Share
The Shrinking Machine
Multiplex, Point of Care and The Speed Factor
Diagnostic Technology Development
The Sepsis Testing Market - A New Direction?
POCT/Self Testing as a Disruptive Force
The Genetics Play - One Test for All Known Infections
Antibiotic Resistance Genes - Simplifying Diagnostics
Molecular Dx - Infectious Disease Recent Developments
Home Test Company Prenetics to go Public
Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio
Lucira Health Posts Revenue Growth on OTC C19 Test
BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform
Talis Biomedical Discusses Point-of-Care
Roche to Acquire GenMark Diagnostics for $1.8B
Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
Hologic to Acquire Mobidiag
Lucira Health Focuses on User Friendly Approach to Home Testing
Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
Fluidigm Plans 'Durable' Diagnostics, Clinical Business
Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
Mammoth Biosciences Developing Pathogen Detection Tech
Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
Scanogen Developing 90 Minute Infection Test
Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
FDA Provides Self Testing SARS-CoV-2 EAU Guidance
Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
Qiagen Respiratory Panel with Coronavirus Receives CE Mark
Lumos Diagnostics Closes $15M Series A Funding
Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay
New Genomic Tests Diagnose Deadly Infections Faster
Biotia Raises $2.4M Seed Round
STDs resurge in US
Ares Genetics signs R&D agreement with leading global IVD corporation
Cell-Free DNA Used for Infectious Disease Testing
One BioMed Raises $5M
Profiles of Key MDx Companies
Abacus Diagnostica
Abbott Diagnostics
Accelerate Diagnostics
Ador Diagnostics
Akonni Biosystems
Alveo Technologies
Applied BioCode
Aus Diagnostics
Beckman Coulter Diagnostics
Becton, Dickinson and Company
Binx Health
Biocartis
bioMerieux Diagnostics
Bio-Rad Laboratories, Inc
Bosch Healthcare Solutions GmbH
Cepheid (now Danaher)
Chembio
Co Diagnostics
Credo Diagnostics Biomedical
Cue Health
Curetis N.V. / Curetis GmbH
Diagenode Diagnostics
Diascopic
Diasorin S.p.A
Eiken Chemical
Enzo Life Sciences, Inc
Eurofins Scientific
Fluxergy
Fulgent Genetics
Fusion Genomics
Genedrive
Genetic Signatures
GenMark Dx
Grifols
Hibergene Diagnostics
Hologic
Illumina
Immunexpress
Inflammatix
Invetech
Janssen Diagnostics
Karius
Lexagene
LightDeck Diagnostics
Luminex Corp
Lumos Diagnostics
Mammoth Biosciences
Maxim Biomedical
Meridian Bioscience
Mesa Biotech
Millipore Sigma
Mindray
Mobidiag
Nanomix
Operon
Oxford Nanopore Technologies
Panagene
Perkin Elmer
Primerdesign
Prominex
Qiagen Gmbh
Quantumdx
Quidel
Roche Molecular Diagnostics
Saw Diagnostics
Seegene
Siemens Healthineers
Sona Nanotech
SpeeDx
T2 Biosystems
Thermo Fisher Scientific Inc
Veramarx
Veredus Laboratories
Vir
XCR Diagnostics
The Infectious Diseases - Market Analysis by Disease
HIV - Human Immunodeficiency Virus (AIDS)
HBV - Hepatitis B
HCV - Hepatitis C
HPV - Human papillomavirus
Influenza
CTGC - Chlamydia/Gonorhea
Tuberculosis
MRSA - Methicillin-resistant Staphylococcus aureus
VRE - Vancomycin-resistant Enterococcus
Blood Screening
COVID-19
Pandemic Diagnostics
Risk Management - Spark and Spread
Dx Technology - Nucleic Acid-Based
Dx Technology - Immunoassay & Serology
Time to Market and Preparedness Issues
Unrecognized Role of Multiplex in Pandemic Management
Industry Overview
Players in a Dynamic Market
Academic Research Lab
Diagnostic Test Developer
Instrumentation Supplier
Distributor and Reagent Supplier
Independent Testing Lab
Public National/regional lab
Hospital lab
Physician Office Labs and Clinics
Audit Body
Certification Body
The Clinical Laboratory Market Segments
Traditional Market Segmentation
Laboratory Focus and Segmentation
Industry Structure
Hospital Testing Share
Economies of Scale
Hospital vs. Central Lab
Physician Office Lab's
Physician's and POCT
For more information about this report visit https://www.researchandmarkets.com/r/58d1bq
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900